Company record
Regeneron Pharmaceuticals Inc
0 FDA warning letters since 2023 and 1 recall in the last 12 months.
Get an email the day FDA posts anything new about Regeneron Pharmaceuticals Inc.
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Aug 26 | Class II | Regeneron Pharmaceuticals Inc Drug |
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regener… Lack of Assurance of Sterility |